CSL struck a collaboration with Alentis to co-develop lixudebart, an anti-fibrosis candidate for life-threatening rare kidney and liver diseases, with $355 million paid upfront plus potential milestone payments reaching $1.2 billion. The structure reinforces CSL’s push into specialty rare disease biology and adds another fibrosis asset aimed at progressing beyond preclinical validation into development with a major pharma partner.